Navigation Links
Sustained virological response linked with improved survival for patients with chronic HCV infection
Date:12/25/2012

Among patients with chronic hepatitis C virus infection and advanced hepatic fibrosis (development of excess fibrous connective tissue), sustained virological response (SVR) to interferon-based treatment was associated with a lower risk of all-cause mortality compared with patients without SVR, according to a study in the December 26 issue of JAMA.

"Chronic hepatitis C virus (HCV) infection is a major cause of cirrhosis, hepatocellular carcinoma (HCC), and end-stage liver disease. The incidence of HCV-related cirrhosis and its complications is expected to increase in upcoming years. Davis et al estimated that currently 25 percent of the approximately 3.5 million U.S. patients with chronic HCV infection have cirrhosis and that the proportion of patients with cirrhosis is likely to increase up to 45 percent by 2030," according to background information in the article.

"Sustained virological response is defined as absence of viremia [the presence of a virus in the blood] 24 weeks after cessation of all antiviral medication. Although SVR has long-term durability, data on the relationship with improved survival to support its use as a surrogate end point of antiviral therapy is scarce. Demonstrating direct clinical benefits would better justify the use of intensive and costly antiviral therapy " the authors write.

Adriaan J. van der Meer, M.D., of Erasmus MC University Medical Center, Rotterdam, the Netherlands and colleagues conducted a study to examine whether achievement of SVR vs. without SVR is associated with a prolonged overall survival in patients with chronic HCV infection and advanced hepatic fibrosis. The study, conducted at five tertiary care hospitals in Europe and Canada, included 530 patients with chronic HCV infection who started an interferon-based treatment regimen between 1990 and 2003, following histological proof of advanced hepatic fibrosis or cirrhosis. Complete follow-up ranged between January 2010 and October 2011. The patients were followed up for a median (midpoint) of 8.4 years. The baseline median age was 48 years and 369 patients (70 percent) were men.

There were 192 patients (36 percent) who achieved SVR; 13 patients with SVR and 100 without SVR died (10-year cumulative all-cause mortality rate, 8.9 percent with SVR and 26.0 percent without SVR). In further analysis, the researchers found that SVR was associated with a reduced risk of all-cause mortality and liver-related mortality or transplantation. Other baseline factors significantly associated with all-cause mortality included older age, HCV genotype 3 infection, presence of diabetes, and a history of severe alcohol use. Of the 100 deaths in patients without SVR, the cause was liver-related in 70 patients (70 percent), not liver-related in 15 percent of patients, and unknown in another 15 percent.

The 10-year cumulative incidence rate of liver-related mortality or transplantation was 1.9 percent with SVR and 27.4 percent without SVR. After 10 years, the cumulative occurrence of HCC was 5.1 percent in patients with SVR and 21.8 percent in patients without SVR. The 10-year cumulative liver failure rate was 2.1 percent in patients with SVR vs. 29.9 percent in patients without SVR.

"In our international, multicenter, long-term follow-up study, SVR was associated with prolonged overall survival. The risk of all-cause mortality was almost 4-fold lower in patients with SVR compared with patients without SVR. Our study with a long follow-up duration demonstrated a lower risk for all-cause mortality in patients with chronic HCV infection and advanced hepatic fibrosis who achieved SVR. In addition, we were able to further establish and quantify the risk reduction of HCC, liver failure, and liver-related mortality or liver transplantation in patients with SVR," the authors conclude.

(JAMA. 2012;308(24):2584-2593; Available pre-embargo to the media at http://media.jamanetwork.com)

Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.


'/>"/>
Contact: Harry L. A. Janssen
h.janssen@erasmusmc.nl
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. Renal denervation achieves significant and sustained blood pressure reduction
2. Cancer cells co-opt immune response to escape destruction
3. NIH scientists reflect on gains in emerging infectious disease awareness, research and response
4. Investigational agent targets gene signaling pathways to improve response for patients with CLL
5. Probiotic Action Issues a Response to an Article on Medical News Today About Synthetic Skin Research
6. Study Tracks Brain Gene Response to Territorial Aggression
7. Researchers develop non-invasive technique for predicting patients response to chemotherapy
8. Genetically-engineered preclinical models predict pharmacodynamic response
9. Feeding microbials to chickens leads to mysterious immune response
10. Adding bavituximab to second-line chemotherapy doubles response rate
11. Trudeau researchers identify unforeseen regulation of the anti-bacterial immune response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... ... July 25, 2017 , ... Facing medical needs with a newborn boy ... advantage of a new benefit for employees that is uncommon in American business: 12 ... company supports me and other employees as new parents. It keeps our family life ...
(Date:7/25/2017)... ... ... SignatureCare Emergency Center – South Austin is treating both adult and pediatric patients ... The Emergency Room opened early March, making it the first SignatureCare Emergency ... are running smoothly,” said Aaron Braun, SignatureCare Emergency Center’s Chief Medical Officer. “We’re glad ...
(Date:7/24/2017)... ... July 24, 2017 , ... Contact: ... Robins & Morton, Perkins Will, Newcomb & Boyd, Walter P Moore and ... new Destination Medical Building located at Mayo Clinic in Jacksonville, Florida. , ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... SignatureCare ... scholarship will be awarded for the fall semester to a deserving student. Get ... Centers Spring 2017 scholarship was awarded to Mariana Castillo who is a nursing student ...
(Date:7/24/2017)... ... July 24, 2017 , ... BayMark Health Services has been ... Administration’s (SAMHSA) State Targeted Response to the Opioid Crisis program. The funding, ... the development of a hub and spoke model for opioid treatment in California. ...
Breaking Medicine News(10 mins):
(Date:7/17/2017)... , July 17, 2017  MedX Holdings, Inc., the ... testing, strengthening and rehabilitation equipment, today announced the national ... MedX is considered the gold standard for the treatment ... specialized medical strengthening equipment. ... with the physician or practice who prescribe the MedX ...
(Date:7/13/2017)... 13, 2017 RK Logistics Group, Inc. was awarded ... for its Fremont, CA headquarters facility ... Tri-Valley and San Jose for hi-tech, ... Fremont , with its Fremont Innovation District, is excited ... a powerful resource to the hundreds of biotech, pharma and ...
(Date:7/11/2017)... , July 11, 2017  Bayer has awarded grants ... countries as part of its prestigious Bayer Hemophilia Awards Program ... of Philadelphia and Uniformed Services University ... are among the winners. Grant recipients were announced last night ... Hemostasis (ISTH) 2017 Congress, Berlin, Germany . ...
Breaking Medicine Technology: